McDermott Advises Biotech Specialist Diagenode on its Sale to US Women’s Health Giant Hologic
McDermott Will & Emery advised Diagenode on its sale to US women’s health giant Hologic (Nasdaq: HOLX). Diagenode is a Liège-based biotech company specializing in the development of molecular diagnostic tests
This acquisition will make the Belgian company “the central focus for the manufacture, research and distribution in Europe” for the American group, a partner of Diagenode since 2016.
The purchase price reached $159 million, or approximately 130 million euros. The shareholders of the Liège-based company include its founder and CEO, Didier Allaer, as well as the Noshaq investment fund (formerly Meusinvest) and the Epimède capital fund.
Diagenode offers more than 30 real-time PCR assays for the detection of bacteria, parasites and viruses. It reached a turnover of 25 million euros in 2020.
In this transaction, McDermott Will & Emery advised Diagenode with a team composed of:
Henri Pieyre de Mandiargues, Anthony Paronneau, partners (Paris), David Lipkin partner (Silicon Valley), Emmanuelle Turek and Sofiya Kachan associates (Paris), in corporate
Antoine Vergnat, partner and Côme de Saint Vincent, associate, in tax (Paris)
Weil Gotshal & Manges advised Hologic in the US, assisted by Stibbe in Belgium.
The Mosal law firm also advised Diagenode on aspects of Belgian law.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.